Business
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
Moleculin Biotech, Inc. Adriano Treve 40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and making them accessible HOUSTON, July 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced the appointment of Adriano Treve as a Strategic Advisor for partnerships. Wi
About this update from Moleculin Biotech, Inc.
[{"type":"image","alt":"Moleculin Biotech, Inc.","displaySize":"","headline":null,"caption":"Moleculin Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/6b5ac38e783ff6d5136647894faf0cc3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/d2AUX0ok9awfDBaq.X9ICQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6b5ac38e783ff6d5136647894faf0cc3","width":300,"height":113}},"lazy":false},{"type":"text","content":"Moleculin Biotech, Inc.","length":23,"tagName":"p"},{"type":"image","alt":"Adriano Treve","displaySize":"","headline":null,"caption":"Adriano Treve","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":190,"url":"https://media.zenfs.com/en/globenewswire.com/529fc328080fc0016664671791442f79"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5ouj6F4anhCwGkyBjHfsIQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM3NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/529fc328080fc0016664671791442f79","width":182,"height":190}}},{"type":"text","content":"40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and making them accessible","length":122,"tagName":"p"},{"type":"text","content":"HOUSTON, July 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced the appointment of Adriano Treve as a Strategic Advisor for partnerships.","length":336,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":190,"url":"https://media.zenfs.com/en/globenewswire.com/e6d484eaa7f7c6736c3df3d0ecded84c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MoXXjRxVz4thTt30bAvtlg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM3NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e6d484eaa7f7c6736c3df3d0ecded84c","width":182,"height":190}}},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"With over four decades of experience at Roche, Mr. Treve brings exceptional leadership and a deep understanding of g...